111 related articles for article (PubMed ID: 30021881)
21. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
Fung SY; Lam JW; Chan KC
Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
[TBL] [Abstract][Full Text] [Related]
22. Growth transformation of primary epithelial cells with a NPC-derived Epstein-Barr virus strain.
Danve C; Decaussin G; Busson P; Ooka T
Virology; 2001 Sep; 288(2):223-35. PubMed ID: 11601894
[TBL] [Abstract][Full Text] [Related]
23. Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells.
Wang HB; Zhang H; Zhang JP; Li Y; Zhao B; Feng GK; Du Y; Xiong D; Zhong Q; Liu WL; Du H; Li MZ; Huang WL; Tsao SW; Hutt-Fletcher L; Zeng YX; Kieff E; Zeng MS
Nat Commun; 2015 Feb; 6():6240. PubMed ID: 25670642
[TBL] [Abstract][Full Text] [Related]
24. In vitro production of stable Epstein-Barr virus-positive epithelial cell clones which resemble the virus:cell interaction observed in nasopharyngeal carcinoma.
Knox PG; Li QX; Rickinson AB; Young LS
Virology; 1996 Jan; 215(1):40-50. PubMed ID: 8553585
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of nasal and nasopharyngeal swab collection for the detection of Epstein-Barr virus in nasopharyngeal carcinoma.
Coghill AE; Wang CP; Verkuijilen SAWM; Yu KJ; Hsu WL; Middeldorp JM; Hildesheim A
J Med Virol; 2018 Jan; 90(1):191-195. PubMed ID: 28833336
[TBL] [Abstract][Full Text] [Related]
26. A single nucleotide polymorphism in the Epstein-Barr virus genome is strongly associated with a high risk of nasopharyngeal carcinoma.
Feng FT; Cui Q; Liu WS; Guo YM; Feng QS; Chen LZ; Xu M; Luo B; Li DJ; Hu LF; Middeldorp JM; Ramayanti O; Tao Q; Cao SM; Jia WH; Bei JX; Zeng YX
Chin J Cancer; 2015 Dec; 34(12):563-72. PubMed ID: 26675171
[TBL] [Abstract][Full Text] [Related]
27. Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma.
Chan KC
Chin J Cancer; 2014 Dec; 33(12):598-603. PubMed ID: 25418194
[TBL] [Abstract][Full Text] [Related]
28. Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia.
Hutajulu SH; Ng N; Jati BR; Fachiroh J; Herdini C; Hariwiyanto B; Haryana SM; Middeldorp JM
J Med Virol; 2012 May; 84(5):768-76. PubMed ID: 22431025
[TBL] [Abstract][Full Text] [Related]
29. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
30. Relationship between PPP1R15A gene polymorphism (rs611251) and Epstein-Barr virus-associated tumors.
Song Y; Liu S; Zhao Z; Zhang Y; Yang Y; Luo B
Acta Virol; 2017; 61(4):445-452. PubMed ID: 29186961
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors.
Hui KF; Tam KP; Chiang AKS
Viruses; 2017 Nov; 9(11):. PubMed ID: 29160853
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the LKB1-AMPK pathway by the Epstein-Barr virus-encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cells.
Lo AK; Lo KW; Ko CW; Young LS; Dawson CW
J Pathol; 2013 Jul; 230(3):336-46. PubMed ID: 23592276
[TBL] [Abstract][Full Text] [Related]
33. SPLUNC1 reduces the inflammatory response of nasopharyngeal carcinoma cells infected with the EB virus by inhibiting the TLR9/NF-κB pathway.
Ou C; Sun Z; Zhang H; Xiong W; Ma J; Zhou M; Lu J; Zeng Z; Bo X; Chen P; Li G; Li X; Li X
Oncol Rep; 2015 Jun; 33(6):2779-88. PubMed ID: 25891128
[TBL] [Abstract][Full Text] [Related]
34. Latent Membrane Protein 1 Is a Novel Determinant of Epstein-Barr Virus Genome Persistence and Reactivation.
Caves EA; Butch RM; Cook SA; Wasil LR; Chen C; Di YP; Lee N; Shair KHY
mSphere; 2017; 2(6):. PubMed ID: 29134204
[TBL] [Abstract][Full Text] [Related]
35. Berberine inhibits the proliferation of human nasopharyngeal carcinoma cells via an Epstein-Barr virus nuclear antigen 1-dependent mechanism.
Wang C; Wang H; Zhang Y; Guo W; Long C; Wang J; Liu L; Sun X
Oncol Rep; 2017 Apr; 37(4):2109-2120. PubMed ID: 28259949
[TBL] [Abstract][Full Text] [Related]
36. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
37. Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens.
Tu C; Zeng Z; Qi P; Li X; Yu Z; Guo C; Xiong F; Xiang B; Zhou M; Gong Z; Liao Q; Yu J; He Y; Zhang W; Li X; Li Y; Li G; Xiong W
J Virol; 2017 Sep; 91(17):. PubMed ID: 28637758
[TBL] [Abstract][Full Text] [Related]
38. Expression of the Epstein-Barr virus (EBV) receptor on the surface of cells infected with EBV derived from nasopharyngeal carcinoma.
Takimoto T; Umeda R
Acta Virol; 1989 Aug; 33(4):314-9. PubMed ID: 2574937
[TBL] [Abstract][Full Text] [Related]
39. Cell-free Epstein-Barr virus-DNA in patients with nasopharyngeal carcinoma: Plasma versus urine.
Sengar M; Chorghe S; Jadhav K; Singh S; Laskar SG; Pai P; Aggarwal JP; D'Cruz A; Chaturvedi P; Deshpande M; Chaukar D; Budrukkar A; Gupta T; Murthy V; Kane S; Thakur M; Rangarajan V; Kannan S; Shet T; Kode J
Head Neck; 2016 Apr; 38 Suppl 1():E1666-73. PubMed ID: 26667883
[TBL] [Abstract][Full Text] [Related]
40. Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma.
Zhang Y; Li WF; Mao YP; Guo R; Tang LL; Peng H; Sun Y; Liu Q; Chen L; Ma J
Oncotarget; 2016 Feb; 7(8):9576-85. PubMed ID: 26840023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
